The physics of low-dose-rate brachytherapy for prostate cancer

Low-dose-rate (LDR) brachytherapy is a form of internal radiotherapy in which tiny radioactive sources are placed directly inside the prostate. For suitable patients, this approach can deliver a concentrated dose to the tumour-bearing gland while limiting exposure to surrounding organs such as the rectum, bladder and urethra.

The physics is governed by source strength, radioactive decay, geometry and tissue attenuation. Iodine-125 and palladium-103 are commonly associated with permanent prostate implants, while cesium-131 is used in some settings. Each isotope has a different half-life and photon energy, so the dose is delivered over a different period and requires carefully matched planning assumptions.

For Australian clinicians, patients and medical physicists, the subject also connects with practical realities: access may differ between Sydney, Melbourne, Brisbane and regional centres; public and private treatment pathways operate side by side; and long-distance travel can influence follow-up planning. Understanding the underlying physics helps teams explain both the benefits and the limitations of this treatment.

How radioactive seeds deliver dose

A permanent prostate implant uses sealed radioactive seeds positioned throughout the gland under image guidance. The sources emit low-energy photons that lose intensity rapidly with distance. This inverse-square behaviour is central to the technique: a seed can provide a high local dose while dose levels fall substantially only a few centimetres away.

The final distribution is created by many overlapping seed contributions rather than by one source. Dose calculations account for the strength and location of each seed, attenuation within tissue, anisotropy around the source and the boundaries of the prostate. Because the prostate is small, millimetre-scale placement errors can affect coverage or increase the dose to nearby structures.

Iodine-125 has a half-life of about 59 days, producing a relatively gradual delivery over several months. Palladium-103 decays more quickly, with a half-life of roughly 17 days. The biological effect depends on dose rate as well as total absorbed dose, making LDR treatment different from a single external-beam fraction even when comparable physical dose concepts are used.

Choosing the isotope and prescription

Isotope selection affects radiation protection, post-implant dose delivery and the timing of follow-up imaging. Lower photon energies reduce penetration outside the treatment field, which is useful for a compact target, although shielding, handling procedures and local regulations remain essential. The treatment team must work with a source calibration traceable to an appropriate standards laboratory.

A prescription is commonly expressed as the intended dose to the prostate, with planning constraints for the urethra and rectum. The physical dose is not the whole story. Radiobiological models consider how continuously declining dose rate influences tumour control and normal-tissue response, while clinical practice relies on validated protocols and outcome data.

For an Australian service, procurement can also matter. Source supply, replacement applicators, ultrasound systems and seed-loading equipment must align with hospital purchasing arrangements and Therapeutic Goods Administration requirements. A centre in Perth or Darwin may face different logistics from one in Melbourne, especially when specialist engineering support or replacement sources must travel interstate.

Planning around anatomy and motion

Transrectal ultrasound is typically used to visualise the prostate during implantation. The planning system converts ultrasound images into a three-dimensional representation of the gland, urethra and rectal wall. Needles are then advanced through a template, allowing seeds to be deposited according to the treatment plan.

The prostate is not a rigid object. It can deform from needle insertion, rectal filling, bladder volume and patient movement. Pubic arch interference may limit access to the lateral or anterior gland, while oedema can alter the apparent volume during the procedure. These factors explain why intraoperative planning and real-time adjustment are so important.

A strong plan balances several competing objectives:

• Cover the clinical target with an adequate margin.
• Keep urethral dose within the department’s accepted limits.
• Reduce dose to the rectal wall and anterior rectum.
• Account for seed displacement and post-implant oedema.
• Produce a reproducible record for quality assurance and review.

Post-implant dosimetry may use computed tomography, magnetic resonance imaging or a combined imaging workflow. The timing of this assessment matters because swelling can make the prostate appear larger soon after implantation. Image registration and contouring uncertainty can therefore influence reported dose-volume indices.

Radiation safety and quality assurance

Although the seeds are low energy, radiation safety remains a structured professional responsibility. Staff follow local rules for source handling, patient instructions, room surveys, contamination prevention and incident reporting. Permanent implants require clear communication about what to do if a seed is expelled, as well as practical advice for close contact during the early period after treatment.

Quality assurance begins before the patient enters the treatment room. It includes source strength verification, ultrasound calibration, template checks, treatment-planning software validation and independent review of the plan. After implantation, a seed count and positional assessment help confirm that the delivered treatment matches the intended arrangement.

Professional development is part of this safety culture. Medical physicists preparing for CCPM examinations would encounter the same broad expectations that support brachytherapy practice: dosimetry, imaging, radiation protection, clinical communication and the ability to evaluate uncertainty rather than simply calculate a number.

Useful checks include:

• Confirming source identity, strength and calibration certificate.
• Verifying the treatment template and needle coordinates.
• Reviewing prostate, urethra and rectum contours.
• Checking planned and implanted seed counts.
• Documenting deviations, corrective actions and follow-up.

Clinical value and patient selection

LDR prostate brachytherapy is generally considered for men with localised disease who have suitable prostate anatomy and urinary function. Risk group, prostate volume, baseline urinary symptoms, previous transurethral surgery and the relationship of the tumour to critical structures all influence selection. It is not a universal substitute for surgery or external-beam radiotherapy.

The physics supports a steep dose gradient, but that advantage depends on accurate placement and appropriate case selection. A large gland, substantial median lobe, obstructive symptoms or difficult pubic arch anatomy may increase technical risk. Hormonal therapy can sometimes reduce prostate volume before implantation, although the decision belongs to the treating multidisciplinary team.

Patients may compare permanent seeds with temporary high-dose-rate brachytherapy, stereotactic external-beam radiotherapy or surgery. Those treatments differ in source behaviour, treatment time, imaging requirements and side-effect patterns. Australian consultations should also account for travel from regional Queensland, rural New South Wales or Tasmania, since urinary symptoms and follow-up appointments may be harder to manage far from the treating centre.

A professional meeting context for brachytherapy

The archived record of COMP’s Banff meeting history reflects the wider culture in which specialist topics are developed: technical presentations, peer discussion, vendor interaction and practical exchange between hospitals. A conference programme on prostate brachytherapy might connect source physics with imaging, treatment planning, commissioning and clinical outcomes.

That exchange is relevant to Australia, where services range from large metropolitan cancer centres to smaller departments that may refer patients for specialised procedures. Local teams often need to adapt international evidence to Australian staffing models, state-based governance, private hospital workflows and the availability of urologists, radiation oncologists and physicists.

Conference materials also show how professional meetings support the technical ecosystem. Even details such as conference bag contents point to the role of equipment suppliers, software developers and educational sponsors in connecting clinical users with tools for imaging, dosimetry and treatment delivery. The technology is valuable only when matched by commissioning discipline and sound clinical judgement.

For Australian practice, the key questions remain concrete:

• Is the patient anatomy appropriate for a permanent implant?
• Can the service maintain reliable source supply and equipment support?
• Are planning, implantation and post-implant review consistently audited?
• Can patients access timely follow-up after returning home?
• Does the department communicate radiation-safety instructions clearly?

Low-dose-rate brachytherapy demonstrates how medical physics turns radioactive decay into a carefully controlled clinical treatment. Its success depends on the interaction of source characteristics, three-dimensional geometry, image quality, biological response and human performance. For patients, that technical chain becomes a treatment experience shaped by preparation, precision and follow-up.

Australian services can strengthen that experience by maintaining transparent patient information, robust multidisciplinary review and regular physics-led quality assurance. Delegates studying the archived COMP material can use the same principles to connect conference learning with daily practice, whether working in a major city hospital or supporting referrals across a wide regional catchment.